in the UK each year. In Britain the age-standardised incidence of breast cancer per 100,000 women was 122 in 2006 [8].
Indication: Breast cancer
Additional Details: early & metastatic HER2+ve disease, subcutaneous formulation
Method(s) of Administration
Subcutaneous
Company Information
Name: Roche
US Name: Roche
NICE Information
In timetable: No
When:
PBR Chemotherapy is tariff excluded.
Service
Implications Available only to registered users
Prescribing
Outlook: Available only to registered users
|
